80 Results for "

bivalent

" in MedChemExpress (MCE) Product Catalog:
Products (80)

80 Results for "bivalent" in MCE Product Catalog:

Cat. No.: HY-169385
CAS No.: 2925060-81-5
Research Areas:  

Cancer

ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
loading...
    loading...
Cat. No.: HY-155447
CAS No.: 136687-43-9
Target:  

Hapten

Research Areas:  

Cancer

AG3.0 is a symmetric di-HSG bivalent hapten. AG3.0 can be used for the research of pretargeted radioimmunotherapy .
loading...
    loading...
Cat. No.: HY-162300
CAS No.: 2922402-05-7
Target:  

EGFR

Research Areas:  

Cancer

EGFR kinase inhibitor 4 (Compound 4) is a bivalent ATP-allosteric EGFR inhibitor (IC50: 1.8 nM for mutant EGFR (LRTMCS)). EGFR kinase inhibitor 4 can be used for research of NSCLC .
loading...
    loading...
Cat. No.: HY-162299
CAS No.: 2922402-03-5
Target:  

EGFR

Research Areas:  

Cancer

EGFR kinase inhibitor 3 (compound 2) is a bivalent ATP-allosteric EGFR kinase inhibitor with IC50s of <10 nM, 1.5 nM, 0.059 nM, 0.064 nM for WT EGFR, EGFR-activating mutations L858R, L858R/T790M and L858R/T790M/C797S, respectively. EGFR kinase inhibitor 3 is a C-linked inhibitor .
loading...
    loading...
Cat. No.: HY-155469
CAS No.: 391267-27-9
Target:  

Hapten

Research Areas:  

Others

IMP 241 is a di-HSG bivalent hapten .
loading...
    loading...
Cat. No.: HY-155445
CAS No.: 136687-39-3
Target:  

Hapten

Research Areas:  

Cancer

di-DTPA TL is a hydrophilic bivalent DTPA hapten that can be used for tumor research .
loading...
    loading...
Cat. No.: HY-155444
Target:  

Histamine Receptor

Research Areas:  

Cancer

AG5.0 is a bivalent hapten contains one HSG (histamine-succinyl-glycyl) group and one DTPA-indium group .
loading...
    loading...
Cat. No.: HY-155468
CAS No.: 159173-58-7
Research Areas:  

Others

AG8.0 is a symmetric di-HSG bivalent hapten. AG8.0 is stable in vivo for 24 h .
loading...
    loading...
Cat. No.: HY-161473
Target:  

Apoptosis

Research Areas:  

Cancer

Apoptosis inducer 16 (Compound 3) is a bivalent Smac mimic that can effectively bind to BIR2 and BIR3, and exhibits cancer cell (apoptosis) inducing activity .
loading...
    loading...
Cat. No.: HY-138865
CAS No.: 119662-55-4
Purity:  98.35%
Target:  

Prion Protein

Research Areas:  

Infection

BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrP Sc) from scrapie-infected cells, with an EC50 of 0.32 μM .
loading...
    loading...
Cat. No.: HY-155471
CAS No.: 608489-42-5
Research Areas:  

Others

IMP 245 is a symmetric di-HSG bivalent hapten. IMP 245 has low toxicity, high affinity binding to available antibodies and absence of cross reactivity or non-specific binding with body components .
loading...
    loading...
Cat. No.: HY-176233
CAS No.: 2765296-93-1
Target:  

Transthyretin (TTR)

Research Areas:  

Cardiovascular Disease

Transthyretin-IN-4 (Compound B26) is a bivalent inhibitor of transthyretin (TTR) amyloidosis (bIC50: 0.09 µM, pIC50: 1.4 µM). Transthyretin-IN-4 is used in the study of fatal heart failure with preserved ejection fraction (HFpEF) and fatal arrhythmias .
loading...
    loading...
Cat. No.: HY-155470
CAS No.: 391267-29-1
Research Areas:  

Cancer

IMP 243 is a symmetric di-HSG (histamine-succinyl-glycine) bivalent hapten containing a Tscg-Cys ligand and two HSG groups. IMP 243 can be radiolabeled with 99mTc-pertechnetate. IMP 243 can be conjugated to other peptides to design bispecific antibodies (bsMAbs) for cancer research .
loading...
    loading...
Cat. No.: HY-133189
CAS No.: 1351373-47-1
Target:  

PROTAC Linkers

Research Areas:  

Endocrinology

Bis-propargyl-PEG9 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG9 can be used to synthesize the bivalent estrogen receptor ligands . Bis-propargyl-PEG9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-173641
CAS No.: 3067681-22-2
Research Areas:  

Cancer

MNN-02-155 is a bivalent molecular glue with with dual binding to p300/CBP and BCL6. MNN-02-155 induces potent activation of the BCL6-target reporter gene and cell death. MNN-02-155 can be used for the study of diffuse large B cell lymphomas (DLBCLs) .
loading...
    loading...
Cat. No.: HY-169386
CAS No.: 2409960-12-7
Target:  

AUTOTACs

Research Areas:  

Cancer

YT 6-2 analog-1 (compound 2-3) is the p62/SQSTM1 targeting, autophagy-targeting ligand (ATL) of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
loading...
    loading...
Cat. No.: HY-155446
Target:  

Hapten

Research Areas:  

Inflammation/Immunology Cancer

di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with 111In (indium) and 131I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled 111In) into the patients .
loading...
    loading...
Cat. No.: HY-130711
CAS No.: 2361119-88-0
Synonyms: VH032-C3-NH2
Research Areas:  

Cancer

(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .
loading...
    loading...
Cat. No.: HY-130711A
CAS No.: 2688842-02-4
Synonyms: VH032-C3-NH2 TFA
Research Areas:  

Cancer

(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader .
loading...
    loading...
Cat. No.: HY-150684
CAS No.: 3031654-49-3
Research Areas:  

Cancer

GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc .
loading...
    loading...